

Jun Yong Park

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/633575/publications.pdf>

Version: 2024-02-01

370
papers

10,743
citations

36303

51
h-index

62596

80
g-index

386
all docs

386
docs citations

386
times ranked

10411
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan). <i>Hepatology</i> , 2011, 53, 885-894.	7.3	329
2	Sarcopenia is associated with significant liver fibrosis independently of obesity and insulin resistance in nonalcoholic fatty liver disease: Nationwide surveys (KNHANES 2008-2011). <i>Hepatology</i> , 2016, 63, 776-786.	7.3	261
3	Performance of Transient Elastography for the Staging of Liver Fibrosis in Patients with Chronic Hepatitis B: A Meta-Analysis. <i>PLoS ONE</i> , 2012, 7, e44930.	2.5	242
4	Validation of FIB-4 and comparison with other simple noninvasive indices for predicting liver fibrosis and cirrhosis in hepatitis B virus-infected patients. <i>Liver International</i> , 2010, 30, 546-553.	3.9	225
5	A Liver Stiffness Measurement-Based, Noninvasive Prediction Model for High-Risk Esophageal Varices in B-Viral Liver Cirrhosis. <i>American Journal of Gastroenterology</i> , 2010, 105, 1382-1390.	0.4	194
6	Lack of difference among terlipressin, somatostatin, and octreotide in the control of acute gastroesophageal variceal hemorrhage. <i>Hepatology</i> , 2014, 60, 954-963.	7.3	169
7	Complete response at first chemoembolization is still the most robust predictor for favorable outcome in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2015, 62, 1304-1310.	3.7	148
8	Controlled attenuation parameter (CAP) for detection of hepatic steatosis in patients with chronic liver diseases: a prospective study of a native Korean population. <i>Liver International</i> , 2014, 34, 102-109.	3.9	143
9	Genome-Wide Association Study Confirming Association of HLA-DP with Protection against Chronic Hepatitis B and Viral Clearance in Japanese and Korean. <i>PLoS ONE</i> , 2012, 7, e39175.	2.5	137
10	A multicenter study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in South Korea. <i>Journal of Hepatology</i> , 2019, 71, 456-464.	3.7	131
11	Usefulness of FibroScan for Detection of Early Compensated Liver Cirrhosis in Chronic Hepatitis B. <i>Digestive Diseases and Sciences</i> , 2009, 54, 1758-1763.	2.3	122
12	Increased risk of hepatocellular carcinoma in chronic hepatitis B patients with transient elastography-defined subclinical cirrhosis. <i>Hepatology</i> , 2015, 61, 1851-1859.	7.3	121
13	Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir. <i>Hepatology</i> , 2011, 53, 1486-1493.	7.3	120
14	Prediction of Development of Liver-Related Events by Transient Elastography in Hepatitis B Patients With Complete Virological Response on Antiviral Therapy. <i>American Journal of Gastroenterology</i> , 2014, 109, 1241-1249.	0.4	120
15	MDM2 and p53 polymorphisms are associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. <i>Carcinogenesis</i> , 2008, 29, 1192-1196.	2.8	119
16	Persistent hepatitis B viral replication affects recurrence of hepatocellular carcinoma after curative resection. <i>Liver International</i> , 2008, 28, 393-401.	3.9	113
17	Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B. <i>Hepatology</i> , 2010, 51, 415-421.	7.3	107
18	Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma. <i>Cancer</i> , 2007, 110, 129-137.	4.1	102

#	ARTICLE	IF	CITATIONS
19	Serotonin signals through a gut-liver axis to regulate hepatic steatosis. <i>Nature Communications</i> , 2018, 9, 4824.	12.8	98
20	Validation of hepatitis B virus-related hepatocellular carcinoma prediction models in the era of antiviral therapy. <i>Hepatology</i> , 2015, 62, 1757-1766.	7.3	97
21	Noninvasive models to predict liver cirrhosis in patients with chronic hepatitis B. <i>Liver International</i> , 2007, 27, 969-976.	3.9	96
22	How Can We Enhance the Performance of Liver Stiffness Measurement Using FibroScan in Diagnosing Liver Cirrhosis in Patients With Chronic Hepatitis B?. <i>Journal of Clinical Gastroenterology</i> , 2010, 44, 66-71.	2.2	94
23	Applicability of BCLC stage for prognostic stratification in comparison with other staging systems: single centre experience from long-term clinical outcomes of 1717 treatment-naïve patients with hepatocellular carcinoma. <i>Liver International</i> , 2012, 32, 1120-1127.	3.9	91
24	Liver Stiffness Measurement Using Acoustic Radiation Force Impulse (ARFI) Elastography and Effect of Necroinflammation. <i>Digestive Diseases and Sciences</i> , 2012, 57, 1682-1691.	2.3	90
25	Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 469-478.	2.3	88
26	Association of non-alcoholic steatohepatitis with subclinical myocardial dysfunction in non-cirrhotic patients. <i>Journal of Hepatology</i> , 2018, 68, 764-772.	3.7	86
27	Prediction of Liver-Related Events Using Fibroscan in Chronic Hepatitis B Patients Showing Advanced Liver Fibrosis. <i>PLoS ONE</i> , 2012, 7, e36676.	2.5	84
28	Outcome after curative resection for a huge (≥10 cm) hepatocellular carcinoma and prognostic significance of gross tumor classification. <i>American Journal of Surgery</i> , 2009, 198, 693-701.	1.8	82
29	Clinical outcomes and predictors for relapse after cessation of oral antiviral treatment in chronic hepatitis B patients. <i>Journal of Gastroenterology</i> , 2016, 51, 830-839.	5.1	78
30	Prediction of postoperative hepatic insufficiency by liver stiffness measurement (FibroScan®) before curative resection of hepatocellular carcinoma: a pilot study. <i>Hepatology International</i> , 2008, 2, 471-7.	4.2	77
31	What are the true normal liver stiffness values using FibroScan®?: a prospective study in healthy living liver and kidney donors in South Korea. <i>Liver International</i> , 2010, 30, 268-274.	3.9	76
32	Addition of tumor multiplicity improves the prognostic performance of the hepatoma arterial embolization prognostic score. <i>Liver International</i> , 2016, 36, 100-107.	3.9	76
33	Prospective comparison of prognostic values of modified Response Evaluation Criteria in Solid Tumours with European Association for the Study of the Liver criteria in hepatocellular carcinoma following chemoembolisation. <i>European Journal of Cancer</i> , 2013, 49, 826-834.	2.8	71
34	Prediction of Recurrence after Curative Resection of Hepatocellular Carcinoma using Liver Stiffness Measurement (FibroScan®). <i>Annals of Surgical Oncology</i> , 2012, 19, 4278-4286.	1.5	70
35	Combined use of AFP, PIVKA-II, and AFP-L3 as tumor markers enhances diagnostic accuracy for hepatocellular carcinoma in cirrhotic patients. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 344-353.	1.5	68
36	Nonalcoholic Fatty Liver Disease and Sarcopenia Are Independently Associated With Cardiovascular Risk. <i>American Journal of Gastroenterology</i> , 2020, 115, 584-595.	0.4	68

#	ARTICLE	IF	CITATIONS
37	Hepatocellular carcinoma presenting with bone metastasis: clinical characteristics and prognostic factors. <i>Journal of Cancer Research and Clinical Oncology</i> , 2008, 134, 1377-1384.	2.5	67
38	Liver Stiffness Measurement in Combination With Noninvasive Markers for the Improved Diagnosis of B-viral Liver Cirrhosis. <i>Journal of Clinical Gastroenterology</i> , 2009, 43, 267-271.	2.2	66
39	Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stop. <i>Clinical and Molecular Hepatology</i> , 2020, 26, 411-429.	8.9	66
40	Long-term adefovir dipivoxil monotherapy for up to 5 years in lamivudine-resistant chronic hepatitis B. <i>Antiviral Therapy</i> , 2010, 15, 235-241.	1.0	64
41	Risk prediction for patients with hepatocellular carcinoma undergoing chemoembolization: development of a prediction model. <i>Liver International</i> , 2016, 36, 92-99.	3.9	64
42	Prospective Validation of ELF Test in Comparison with Fibroscan and FibroTest to Predict Liver Fibrosis in Asian Subjects with Chronic Hepatitis B. <i>PLoS ONE</i> , 2012, 7, e41964.	2.5	64
43	Prognostic value of α -fetoprotein and des- γ -carboxy prothrombin responses in patients with hepatocellular carcinoma treated with transarterial chemoembolization. <i>BMC Cancer</i> , 2013, 13, 5.	2.6	60
44	Prognostic value of the 7th edition of the AJCC staging system as a clinical staging system in patients with hepatocellular carcinoma. <i>European Journal of Cancer</i> , 2011, 47, 2568-2575.	2.8	59
45	Long-term clinical outcomes of hepatic arterial infusion chemotherapy with cisplatin with or without 5-fluorouracil in locally advanced hepatocellular carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2011, 137, 659-667.	2.5	57
46	Prognostic significance of the worst grade in hepatocellular carcinoma with heterogeneous histologic grades of differentiation. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 1384-1390.	2.8	57
47	Prognostic value of ^{18}F -FDG PET for hepatocellular carcinoma patients treated with sorafenib. <i>Liver International</i> , 2011, 31, 1144-1149.	3.9	56
48	Risk Assessment of Esophageal Variceal Bleeding in B-Viral Liver Cirrhosis by a Liver Stiffness Measurement-Based Model. <i>American Journal of Gastroenterology</i> , 2011, 106, 1654-1662.	0.4	56
49	A randomized comparative study of high-dose and low-dose hepatic arterial infusion chemotherapy for intractable, advanced hepatocellular carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 65, 373-382.	2.3	55
50	Early α -fetoprotein response as a predictor for clinical outcome after localized concurrent chemoradiotherapy for advanced hepatocellular carcinoma. <i>Liver International</i> , 2011, 31, 369-376.	3.9	55
51	Normal liver elasticity values using acoustic radiation force impulse imaging: A prospective study in healthy living liver and kidney donors. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 130-136.	2.8	53
52	Surgical Resection After Down-Staging of Locally Advanced Hepatocellular Carcinoma by Localized Concurrent Chemoradiotherapy. <i>Annals of Surgical Oncology</i> , 2014, 21, 3646-3653.	1.5	53
53	Clinical Significance of AFP and PIVKA-II Responses for Monitoring Treatment Outcomes and Predicting Prognosis in Patients with Hepatocellular Carcinoma. <i>BioMed Research International</i> , 2013, 2013, 1-6.	1.9	52
54	Liver stiffness measurement using FibroScan [®] is influenced by serum total bilirubin in acute hepatitis. <i>Liver International</i> , 2009, 29, 810-815.	3.9	51

#	ARTICLE	IF	CITATIONS
55	Characterization of focal liver masses using acoustic radiation force impulse elastography. <i>World Journal of Gastroenterology</i> , 2013, 19, 219.	3.3	51
56	Clinical Features and Prognosis of Spontaneous Bacterial Peritonitis in Korean Patients with Liver Cirrhosis: A Multicenter Retrospective Study. <i>Gut and Liver</i> , 2009, 3, 197-204.	2.9	51
57	Specific mutations in the enhancer II/core promoter/precore regions of hepatitis B virus subgenotype C2 in Korean patients with hepatocellular carcinoma. <i>Journal of Medical Virology</i> , 2009, 81, 1002-1008.	5.0	50
58	The Accuracy of Noninvasive Methods in Predicting the Development of Hepatocellular Carcinoma and Hepatic Decompensation in Patients With Chronic Hepatitis B. <i>Journal of Clinical Gastroenterology</i> , 2012, 46, 518-525.	2.2	49
59	Liver fibrosis assessed with transient elastography is an independent risk factor for ischemic stroke. <i>Atherosclerosis</i> , 2017, 260, 156-162.	0.8	49
60	Prediction of Sustained Response After Nucleo(s)tide Analogue Cessation Using HBsAg and HBcrAg Levels: A Multicenter Study (CREATE). <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e784-e793.	4.4	49
61	Factors associated with significant liver fibrosis assessed using transient elastography in general population. <i>World Journal of Gastroenterology</i> , 2015, 21, 1158.	3.3	48
62	¹⁸ F-fluorodeoxyglucose uptake on positron emission tomography as a prognostic predictor in locally advanced hepatocellular carcinoma. <i>Cancer</i> , 2011, 117, 4779-4787.	4.1	47
63	Efficacy of adefovir add-on lamivudine rescue therapy compared with switching to entecavir monotherapy in patients with lamivudine-resistant chronic hepatitis B. <i>Journal of Medical Virology</i> , 2010, 82, 1835-1842.	5.0	46
64	Prospective Validation of FibroTest in Comparison with Liver Stiffness for Predicting Liver Fibrosis in Asian Subjects with Chronic Hepatitis B. <i>PLoS ONE</i> , 2012, 7, e35825.	2.5	45
65	Histological subclassification of cirrhosis can predict recurrence after curative resection of hepatocellular carcinoma. <i>Liver International</i> , 2014, 34, 1008-1017.	3.9	44
66	Efficient long-term amplification of hepatitis B virus isolates after infection of slow proliferating HepG2-NTCP cells. <i>Journal of Hepatology</i> , 2019, 71, 289-300.	3.7	44
67	Efficacy and safety of glecaprevir/pibrentasvir in renally impaired patients with chronic HCV infection. <i>Liver International</i> , 2020, 40, 1032-1041.	3.9	44
68	Predictive factors for long-term survival in patients with clinically significant portal hypertension following resection of hepatocellular carcinoma. <i>Liver International</i> , 2011, 31, 485-493.	3.9	43
69	Extremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immune-tolerant phase. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 196-204.	3.7	43
70	Non-invasive assessment of changes in liver fibrosis via liver stiffness measurement in patients with chronic hepatitis B: impact of antiviral treatment on fibrosis regression. <i>Hepatology International</i> , 2010, 4, 673-680.	4.2	42
71	Gastrointestinal Complications After Concurrent Chemoradiation Therapy in Patients With Hepatocellular Carcinoma: Endoscopic Findings and Risk Factors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, 1343-1351.	0.8	42
72	Survival of Hepatocellular Carcinoma Patients May be Improved in Surveillance Interval not More Than 6 Months Compared With More Than 6 Months. <i>Journal of Clinical Gastroenterology</i> , 2013, 47, 538-544.	2.2	42

#	ARTICLE	IF	CITATIONS
73	Genetic alterations and their clinical implications in gastric cancer peritoneal carcinomatosis revealed by whole-exome sequencing of malignant ascites. <i>Oncotarget</i> , 2016, 7, 8055-8066.	1.8	42
74	Improvement of Liver Fibrosis after Long-Term Antiviral Therapy Assessed by Fibroscan in Chronic Hepatitis B Patients With Advanced Fibrosis. <i>American Journal of Gastroenterology</i> , 2017, 112, 882-891.	0.4	42
75	Hepatocellular carcinoma in Budd-Chiari syndrome: A single center experience with long-term follow-up in South Korea. <i>World Journal of Gastroenterology</i> , 2012, 18, 1946.	3.3	42
76	Current Status and Future Direction of Immunotherapy in Hepatocellular Carcinoma: What Do the Data Suggest?. <i>Immune Network</i> , 2020, 20, e11.	3.6	42
77	No association for Chinese HBV-related hepatocellular carcinoma susceptibility SNP in other East Asian populations. <i>BMC Medical Genetics</i> , 2012, 13, 47.	2.1	40
78	Functions of human liver CD69+CD103-CD8+ T cells depend on HIF-2 β activity in healthy and pathologic livers. <i>Journal of Hepatology</i> , 2020, 72, 1170-1181.	3.7	39
79	Number of Target Lesions for EASL and Modified RECIST to Predict Survivals in Hepatocellular Carcinoma Treated with Chemoembolization. <i>Clinical Cancer Research</i> , 2013, 19, 1503-1511.	7.0	38
80	Liver injury in acute hepatitis A is associated with decreased frequency of regulatory T cells caused by Fas-mediated apoptosis. <i>Gut</i> , 2015, 64, 1303-1313.	12.1	38
81	Ascitic fluid infection in patients with hepatitis B virus-related liver cirrhosis: Culture-negative neutrocytic ascites versus spontaneous bacterial peritonitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 122-128.	2.8	37
82	Risk assessment of clinical outcomes in Asian patients with chronic hepatitis B using enhanced liver fibrosis test. <i>Hepatology</i> , 2014, 60, 1911-1919.	7.3	37
83	Validation of PAGE model in Asian chronic hepatitis B patients receiving entecavir or tenofovir. <i>Liver International</i> , 2017, 37, 1788-1795.	3.9	37
84	<i>Wisteria floribunda</i> agglutinin-positive human Mac-2 binding protein predicts the risk of HBV-related liver cancer development. <i>Liver International</i> , 2017, 37, 879-887.	3.9	37
85	Gamma-glutamyl transpeptidase-to-platelet ratio is an independent predictor of hepatitis B virus-related liver cancer. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1221-1229.	2.8	37
86	Development of a New Nomogram Including Neutrophil-to-Lymphocyte Ratio to Predict Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. <i>Cancers</i> , 2019, 11, 509.	3.7	37
87	Cardiovascular Risk Is Elevated in Lean Subjects with Nonalcoholic Fatty Liver Disease. <i>Gut and Liver</i> , 2022, 16, 290-299.	2.9	37
88	Natural history of hepatitis B virus-related cirrhotic patients hospitalized to control ascites. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, 1722-1727.	2.8	36
89	Role of surgical resection for multiple hepatocellular carcinomas. <i>World Journal of Gastroenterology</i> , 2013, 19, 366.	3.3	36
90	Impact of Spontaneous Hepatocellular Carcinoma Rupture on Recurrence Pattern and Long-term Surgical Outcomes after Partial Hepatectomy. <i>World Journal of Surgery</i> , 2014, 38, 2070-2078.	1.6	36

#	ARTICLE	IF	CITATIONS
91	Conventional versus drug-eluting beads chemoembolization for hepatocellular carcinoma: Emphasis on the impact of tumor size. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 487-496.	2.8	36
92	Clinical characteristics and prognosis of hepatocellular carcinoma with different sets of serum AFP and PIVKA-II levels. <i>European Journal of Gastroenterology and Hepatology</i> , 2012, 24, 849-856.	1.6	35
93	Combined measurement of preoperative Î±fetoprotein and desÎ³-carboxy prothrombin predicts recurrence after curative resection in patients with hepatitis B-related hepatocellular carcinoma. <i>International Journal of Cancer</i> , 2012, 131, 2332-2341.	5.1	35
94	Human liver CD8+ MAIT cells exert TCR/MR1-independent innate-like cytotoxicity in response to IL-15. <i>Journal of Hepatology</i> , 2020, 73, 640-650.	3.7	35
95	Liver stiffness-based model for prediction of hepatocellular carcinoma in chronic hepatitis B virus infection: comparison with histological fibrosis. <i>Liver International</i> , 2015, 35, 1054-1062.	3.9	34
96	Lower Incidence of Hepatocellular Carcinoma and Cirrhosis in Hepatitis C Patients with Sustained Virological Response by Pegylated Interferon and Ribavirin. <i>Digestive Diseases and Sciences</i> , 2015, 60, 573-581.	2.3	34
97	Prevalence and genotype distribution of hepatitis C virus among apparently healthy individuals in Mongolia: a population-based nationwide study. <i>Liver International</i> , 2008, 28, 1389-1395.	3.9	33
98	Combination treatment of localized concurrent chemoradiation therapy and transarterial chemoembolization in locally advanced hepatocellular carcinoma with intrahepatic metastasis. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 165-173.	2.3	33
99	Serum Dickkopf-1 as a Biomarker for the Diagnosis of Hepatocellular Carcinoma. <i>Yonsei Medical Journal</i> , 2015, 56, 1296.	2.2	33
100	Factors Affecting the Accuracy of Controlled Attenuation Parameter (CAP) in Assessing Hepatic Steatosis in Patients with Chronic Liver Disease. <i>PLoS ONE</i> , 2014, 9, e98689.	2.5	33
101	Efficacy and Safety of Transarterial Chemoembolization in Recurrent Hepatocellular Carcinoma After Curative Surgical Resection. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2009, 32, 564-569.	1.3	32
102	Predictive value of <sc>HBsAg</sc> quantification for determining the clinical course of genotype C <sc>HBeAg</sc>-negative carriers. <i>Liver International</i> , 2012, 32, 796-802.	3.9	32
103	Long-term changes of liver stiffness values assessed using transient elastography in patients with chronic hepatitis B receiving entecavir. <i>Liver International</i> , 2014, 34, 1216-1223.	3.9	32
104	A Novel Model to Predict Esophageal Varices in Patients with Compensated Cirrhosis Using Acoustic Radiation Force Impulse Elastography. <i>PLoS ONE</i> , 2015, 10, e0121009.	2.5	32
105	Association Between Level of Fibrosis, Rather Than Antiviral Regimen, and Outcomes of Patients With Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1647-1656.e6.	4.4	32
106	Liver Fibrosis, Not Steatosis, Associates with Long-Term Outcomes in Ischaemic Stroke Patients. <i>Cerebrovascular Diseases</i> , 2019, 47, 32-39.	1.7	32
107	A novel liver stiffness measurement-based prediction model for cirrhosis in hepatitis B patients. <i>Liver International</i> , 2010, 30, 1073-1081.	3.9	31
108	The Relationship between Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease Measured by Controlled Attenuation Parameter. <i>Yonsei Medical Journal</i> , 2016, 57, 885.	2.2	31

#	ARTICLE	IF	CITATIONS
109	Influence of hepatic steatosis on the outcomes of patients with chronic hepatitis B treated with entecavir and tenofovir. <i>Clinical and Molecular Hepatology</i> , 2019, 25, 283-293.	8.9	31
110	A survey on transarterial chemoembolization refractoriness and a real-world treatment pattern for hepatocellular carcinoma in Korea. <i>Clinical and Molecular Hepatology</i> , 2020, 26, 24-32.	8.9	31
111	Early on-treatment predictions of clinical outcomes using alpha-fetoprotein and des-gamma-carboxy prothrombin responses in patients with advanced hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 313-322.	2.8	30
112	Rituximab and hepatitis B reactivation in HBsAg-negative/ anti-HBc-positive kidney transplant recipients. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, 722-729.	0.7	30
113	Hepatocellular Carcinoma Risk Steadily Persists over Time Despite Long-Term Antiviral Therapy for Hepatitis B: A Multicenter Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 832-837.	2.5	30
114	Normal liver stiffness values differ between men and women: A prospective study for healthy living liver and kidney donors in a native Korean population. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 781-788.	2.8	29
115	Red cell volume distribution width to platelet ratio in assessment of liver fibrosis in patients with chronic hepatitis B. <i>Liver International</i> , 2016, 36, 24-30.	3.9	29
116	External validation of the modified PACE score in Asian chronic hepatitis B patients receiving antiviral therapy. <i>Liver International</i> , 2019, 39, 1624-1630.	3.9	29
117	Early on-treatment change in liver stiffness predicts development of liver-related events in chronic hepatitis B patients receiving antiviral therapy. <i>Liver International</i> , 2013, 33, 180-189.	3.9	28
118	Hepatic fibrosis assessed using transient elastography independently associated with coronary artery calcification. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1536-1542.	2.8	28
119	Use of Wisteria Floribunda Agglutinin-Positive Human Mac-2 Binding Protein in Assessing Risk of Hepatocellular Carcinoma Due to Hepatitis B Virus. <i>Medicine (United States)</i> , 2016, 95, e3328.	1.0	28
120	Risk stratification using sarcopenia status among subjects with metabolic dysfunction-associated fatty liver disease. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2021, 12, 1168-1178.	7.3	28
121	Clinicopathological Characteristics in Combined Hepatocellular-Cholangiocarcinoma: A Single Center Study in Korea. <i>Yonsei Medical Journal</i> , 2011, 52, 753.	2.2	27
122	Inhibition of tumour angiogenesis and growth by small hairpin $\text{HIF-1}\alpha$ and IL-8 in hepatocellular carcinoma. <i>Liver International</i> , 2014, 34, 632-642.	3.9	27
123	Safety of Tocilizumab in Rheumatoid Arthritis Patients with Resolved Hepatitis B Virus Infection: Data from Real-World Experience. <i>Yonsei Medical Journal</i> , 2018, 59, 452.	2.2	27
124	Association between IL28B Polymorphisms and Spontaneous Clearance of Hepatitis B Virus Infection. <i>PLoS ONE</i> , 2013, 8, e69166.	2.5	26
125	Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first-line therapy: A Korean multicenter study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1463-1469.	2.8	26
126	Prognosis of hepatocellular carcinoma patients with extrahepatic metastasis and the controllability of intrahepatic lesions. <i>Clinical and Experimental Metastasis</i> , 2014, 31, 475-482.	3.3	26

#	ARTICLE	IF	CITATIONS
127	Comprehensive immune profiling and immune-monitoring using body fluid of patients with metastatic gastric cancer. , 2019, 7, 268.		26
128	Efficacy of Lenervimab, a Recombinant Human Immunoglobulin, in Treatment of Chronic Hepatitis B Virus Infection. Clinical Gastroenterology and Hepatology, 2020, 18, 3043-3045.e1.	4.4	26
129	The efficacies of entecavir and tenofovir in terms of enhancing prognosis after curative treatment of hepatitis B virus-related hepatocellular carcinoma. European Journal of Internal Medicine, 2021, 89, 48-55.	2.2	26
130	Rescue Monotherapy in Lamivudine-Resistant Hepatitis B e Antigen-Positive Chronic Hepatitis B: Adefovir versus Entecavir. Antiviral Therapy, 2009, 14, 705-712.	1.0	26
131	The clinical significance of ascitic fluid CEA in advanced gastric cancer with ascites. Journal of Cancer Research and Clinical Oncology, 2010, 136, 517-526.	2.5	25
132	Use of the Delta Neutrophil Index as a Prognostic Factor of Mortality in Patients with Spontaneous Bacterial Peritonitis: Implications of a Simple and Useful Marker. PLoS ONE, 2014, 9, e86884.	2.5	25
133	Relationship between Cerebral Microbleeds and Liver Stiffness Determined by Transient Elastography. PLoS ONE, 2015, 10, e0139227.	2.5	25
134	Development and validation of a prognostic model for patients with hepatocellular carcinoma undergoing radiofrequency ablation. Cancer Medicine, 2019, 8, 5023-5032.	2.8	25
135	Liver Stiffness Value-Based Risk Estimation of Late Recurrence after Curative Resection of Hepatocellular Carcinoma: Development and Validation of a Predictive Model. PLoS ONE, 2014, 9, e99167.	2.5	24
136	Risk Assessment of Liver-related Events Using Transient Elastography in Patients With Chronic Hepatitis B Receiving Entecavir. Journal of Clinical Gastroenterology, 2014, 48, 272-278.	2.2	24
137	Early α -fetoprotein response predicts survival in patients with advanced hepatocellular carcinoma treated with sorafenib. Journal of Hepatocellular Carcinoma, 2015, 2, 39.	3.7	24
138	Effects of Entecavir and Tenofovir on Renal Function in Patients with Hepatitis B Virus-Related Compensated and Decompensated Cirrhosis. Gut and Liver, 2017, 11, 828-834.	2.9	24
139	Additional fibrate treatment in UDCA-refractory PBC patients. Liver International, 2019, 39, 1776-1785.	3.9	24
140	Validation of the CAMD Score in Patients With Chronic Hepatitis B Virus Infection Receiving Antiviral Therapy. Clinical Gastroenterology and Hepatology, 2020, 18, 693-699.e1.	4.4	24
141	The relationship between visceral obesity and hepatic steatosis measured by controlled attenuation parameter. PLoS ONE, 2017, 12, e0187066.	2.5	24
142	Subcirrhotic liver stiffness by FibroScan correlates with lower risk of hepatocellular carcinoma in patients with HBV-related cirrhosis. Hepatology International, 2017, 11, 268-276.	4.2	23
143	An optimized hepatocellular carcinoma prediction model for chronic hepatitis B with well-controlled viremia. Liver International, 2020, 40, 1736-1743.	3.9	23
144	Transient elastography-based risk estimation of hepatitis B virus-related occurrence of hepatocellular carcinoma: development and validation of a predictive model. OncoTargets and Therapy, 2013, 6, 1463.	2.0	22

#	ARTICLE	IF	CITATIONS
145	Use of transient elastography to predict de novo recurrence after radiofrequency ablation for hepatocellular carcinoma. <i>OncoTargets and Therapy</i> , 2015, 8, 347.	2.0	22
146	Prognostic role of magnetic resonance imaging vs. computed tomography for hepatocellular carcinoma undergoing chemoembolization. <i>Liver International</i> , 2015, 35, 1722-1730.	3.9	22
147	Tumor Necrosis Factor-producing T-regulatory Cells AreAssociated With Severe Liver Injury in Patients With AcuteHepatitis A. <i>Gastroenterology</i> , 2018, 154, 1047-1060.	1.3	22
148	Feasibility of dynamic risk prediction for hepatocellular carcinoma development in patients with chronic hepatitis B. <i>Liver International</i> , 2018, 38, 676-686.	3.9	22
149	Lenvatinib is independently associated with the reduced risk of progressive disease when compared with sorafenib in patients with advanced hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 1317-1325.	2.8	22
150	Hepatic Steatosis Index in the Detection of Fatty Liver in Patients with Chronic Hepatitis B Receiving Antiviral Therapy. <i>Gut and Liver</i> , 2021, 15, 117-127.	2.9	22
151	YAP/TAZ Suppress Drug Penetration Into Hepatocellular Carcinoma Through Stromal Activation. <i>Hepatology</i> , 2021, 74, 2605-2621.	7.3	22
152	Dickkopf-1 induces angiogenesis via VEGF receptor 2 regulation independent of the Wnt signaling pathway. <i>Oncotarget</i> , 2017, 8, 58974-58984.	1.8	22
153	Subclassification of Barcelona Clinic Liver Cancer B and C hepatocellular carcinoma: A cohort study of the multicenter registry database. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 842-847.	2.8	21
154	Prognosis of Early-Stage Hepatocellular Carcinoma: Comparison between Trans-Arterial Chemoembolization and Radiofrequency Ablation. <i>Cancers</i> , 2020, 12, 2527.	3.7	21
155	Partial virological response to entecavir in treatment-naïve patients with chronic hepatitis B. <i>Antiviral Therapy</i> , 2011, 16, 469-477.	1.0	20
156	Adjuvant Hepatic Arterial Infusional Chemotherapy with 5-Fluorouracil and Cisplatin after Curative Resection of Hepatocellular Carcinoma. <i>Oncology</i> , 2011, 81, 184-191.	1.9	20
157	Risk Assessment of Development of Hepatic Decompensation in Histologically Proven Hepatitis B Viral Cirrhosis Using Liver Stiffness Measurement. <i>Digestion</i> , 2012, 85, 219-227.	2.3	20
158	18F-FDG PET Metabolic Parameters and MRI Perfusion and Diffusion Parameters in Hepatocellular Carcinoma: A Preliminary Study. <i>PLoS ONE</i> , 2013, 8, e71571.	2.5	20
159	Efficacy of Sorafenib Monotherapy versus Sorafenib-Based Loco-Regional Treatments in Advanced Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2013, 8, e77240.	2.5	20
160	Lesson from 610 liver resections of hepatocellular carcinoma in a single center over 10â€years. <i>World Journal of Surgical Oncology</i> , 2014, 12, 192.	1.9	20
161	Entecavir plus tenofovir combination therapy in patients with multidrugâ€resistant chronic hepatitis <sc>B</sc>: results of a multicentre, prospective study. <i>Liver International</i> , 2016, 36, 1108-1115.	3.9	20
162	Comparison between chronic hepatitis B patients with untreated immune-tolerant phase vs. those with virological response by antivirals. <i>Scientific Reports</i> , 2019, 9, 2508.	3.3	20

#	ARTICLE	IF	CITATIONS
163	Early reduction of regulatory T cells is associated with acute rejection in liver transplantation under tacrolimus-based immunosuppression with basiliximab induction. American Journal of Transplantation, 2020, 20, 2058-2069.	4.7	20
164	Serum Wisteria floribunda agglutinin-positive human Mac-2 binding protein level predicts recurrence of hepatitis B virus-related hepatocellular carcinoma after curative resection. Clinical and Molecular Hepatology, 2020, 26, 33-44.	8.9	20
165	Risk assessment of hepatocellular carcinoma development for indeterminate hepatic nodules in patients with chronic hepatitis B. Clinical and Molecular Hepatology, 2019, 25, 390-399.	8.9	20
166	The Modified Response Evaluation Criteria in Solid Tumors (RECIST) Yield a More Accurate Prognoses Than the RECIST 1.1 in Hepatocellular Carcinoma Treated with Transarterial Radioembolization. Gut and Liver, 2020, 14, 765-774.	2.9	20
167	Hepatitis B e antigen-negative mutations in the precore and core promoter regions in Korean patients. Journal of Medical Virology, 2009, 81, 594-601.	5.0	19
168	Variability in liver stiffness values from different intercostal spaces. Liver International, 2009, 29, 760-766.	3.9	19
169	Abnormal Liver Stiffness Assessed Using Transient Elastography (Fibroscan®) in HIV-Infected Patients without HBV/HCV Coinfection Receiving Combined Antiretroviral Treatment. PLoS ONE, 2013, 8, e52720.	2.5	19
170	Diffusion and perfusion MRI prediction of progression-free survival in patients with hepatocellular carcinoma treated with concurrent chemoradiotherapy. Journal of Magnetic Resonance Imaging, 2014, 39, 286-292.	3.4	19
171	Knockdown of HIF-1 α and IL-8 induced apoptosis of hepatocellular carcinoma triggers apoptosis of vascular endothelial cells. Apoptosis: an International Journal on Programmed Cell Death, 2016, 21, 85-95.	4.9	19
172	Serum cystatin C level: An excellent predictor of mortality in patients with cirrhotic ascites. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 910-917.	2.8	19
173	Staged partial hepatectomy versus transarterial chemoembolization for the treatment of spontaneous hepatocellular carcinoma rupture: a multicenter analysis in Korea. Annals of Surgical Treatment and Research, 2019, 96, 275.	1.0	19
174	Efficacy and Safety of Liver-Directed Concurrent Chemoradiotherapy and Sequential Sorafenib for Advanced Hepatocellular Carcinoma: A Prospective Phase 2 Trial. International Journal of Radiation Oncology Biology Physics, 2020, 107, 106-115.	0.8	19
175	Negligible risks of hepatocellular carcinoma during biomarker-defined immune-tolerant phase for patients with chronic hepatitis B. Clinical and Molecular Hepatology, 2021, 27, 295-304.	8.9	19
176	Sarcopenia Is Independently Associated with the Degree of Liver Fibrosis in Patients with Type 2 Diabetes Mellitus. Gut and Liver, 2020, 14, 626-635.	2.9	19
177	Prognostic value of the combined use of transient elastography and fibrotest in patients with chronic hepatitis B. Liver International, 2015, 35, 455-462.	3.9	18
178	Prevalence and Predictors of Significant Fibrosis Among Subjects with Transient Elastography-Defined Nonalcoholic Fatty Liver Disease. Digestive Diseases and Sciences, 2017, 62, 2150-2158.	2.3	18
179	Using transient elastography to predict hepatocellular carcinoma recurrence after radiofrequency ablation. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 1079-1086.	2.8	18
180	Hepatic Decompensation in Cirrhotic Patients Receiving Antiviral Therapy for Chronic Hepatitis B. Clinical Gastroenterology and Hepatology, 2021, 19, 1950-1958.e7.	4.4	18

#	ARTICLE	IF	CITATIONS
181	Advanced Liver Fibrosis Predicts Unfavorable Long-Term Prognosis in First-Ever Ischemic Stroke or Transient Ischemic Attack. <i>Cerebrovascular Diseases</i> , 2020, 49, 474-480.	1.7	18
182	Impact of tenofovir alafenamide vs. entecavir on hepatocellular carcinoma risk in patients with chronic hepatitis B. <i>Hepatology International</i> , 2021, 15, 1083-1092.	4.2	18
183	Progression of Untreated Minimally Active Chronic HBV Infection Compared to Inactive Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2808-2810.e2.	4.4	17
184	Prognosis of Untreated Minimally Active Chronic Hepatitis B Patients in Comparison With Virological Responders by Antivirals. <i>Clinical and Translational Gastroenterology</i> , 2019, 10, e00036.	2.5	17
185	Fibrosis-4 index at diagnosis can predict all-cause mortality in patients with rheumatoid arthritis: A retrospective monocentric study. <i>Modern Rheumatology</i> , 2020, 30, 70-77.	1.8	17
186	Dynamics of the Liver Stiffness Value Using Transient Elastography during the Perioperative Period in Patients with Valvular Heart Disease. <i>PLoS ONE</i> , 2014, 9, e92795.	2.5	17
187	Factors Influencing the Diagnostic Accuracy of Acoustic Radiation Force Impulse Elastography in Patients with Chronic Hepatitis B. <i>Gut and Liver</i> , 2016, 10, 275.	2.9	17
188	Prospective validation of P2/MS noninvasive index using complete blood counts for detecting oesophageal varices in B-viral cirrhosis. <i>Liver International</i> , 2010, 30, 860-866.	3.9	16
189	How Many Valid Measurements Are Necessary to Assess Liver Fibrosis Using FibroScan® in Patients with Chronic Viral Hepatitis? An Analysis of Subjects with at Least 10 Valid Measurements. <i>Yonsei Medical Journal</i> , 2012, 53, 337.	2.2	16
190	Antibody-Secreting Cells with a Phenotype of Ki-67low, CD138high, CD31high, and CD38high Secrete Nonspecific IgM during Primary Hepatitis A Virus Infection. <i>Journal of Immunology</i> , 2013, 191, 127-134.	0.8	16
191	Long-term outcomes of chronic hepatitis B virus infection in the era of antiviral therapy in Korea. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1005-1011.	2.8	16
192	Reproducibility of European Association for the Study of the Liver criteria and modified Response Evaluation Criteria in Solid Tumors in patients treated with sorafenib. <i>Liver International</i> , 2018, 38, 1655-1663.	3.9	16
193	Effects of rituximab dose on hepatitis B reactivation in patients with resolved infection undergoing immunologic incompatible kidney transplantation. <i>Scientific Reports</i> , 2018, 8, 15629.	3.3	16
194	Cutaneous Metastasis from Cholangiocarcinoma as the First Clinical Sign: A Report of Two Cases. <i>Gut and Liver</i> , 2011, 5, 100-104.	2.9	16
195	Predicting Liver-Related Events Using Transient Elastography in Chronic Hepatitis C Patients with Sustained Virological Response. <i>Gut and Liver</i> , 2016, 10, 429-36.	2.9	16
196	Can preoperative diffusion-weighted MRI predict postoperative hepatic insufficiency after curative resection of HBV-related hepatocellular carcinoma? A pilot study. <i>Magnetic Resonance Imaging</i> , 2010, 28, 802-811.	1.8	15
197	Clinical Efficacy of a 24-months Course of Lamivudine Therapy in Patients with HBeAg Negative Chronic Hepatitis B: A Long-term Prospective Study. <i>Journal of Korean Medical Science</i> , 2010, 25, 882.	2.5	15
198	Optimal Time for Restoring the Reliability of Liver Stiffness Measurement in Patients With Chronic Hepatitis B Experiencing Acute Exacerbation. <i>Journal of Clinical Gastroenterology</i> , 2012, 46, 602-607.	2.2	15

#	ARTICLE	IF	CITATIONS
199	Regulation of the hypoxic tumor environment in hepatocellular carcinoma using RNA interference. <i>Cancer Cell International</i> , 2017, 17, 3.	4.1	15
200	Transarterial Radioembolization Versus Concurrent Chemoradiation Therapy for Locally Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 396-406.	0.8	15
201	Alpha-Fetoprotein, Des-Gamma-Carboxy Prothrombin, and Modified RECIST Response as Predictors of Survival after Transarterial Radioembolization for Hepatocellular Carcinoma. <i>Journal of Vascular and Interventional Radiology</i> , 2019, 30, 1194-1200.e1.	0.5	15
202	Controlled attenuation parameter value and the risk of hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy. <i>Hepatology International</i> , 2021, 15, 892-900.	4.2	15
203	Effect of tenofovir alafenamide vs. tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1570-1578.	2.0	15
204	Hepatocellular Carcinoma in Korea Between 2008 and 2011: an Analysis of Korean Nationwide Cancer Registry. <i>Journal of Liver Cancer</i> , 2020, 20, 41-52.	1.1	15
205	Hepatocellular Carcinoma in Korea between 2012 and 2014: an Analysis of Data from the Korean Nationwide Cancer Registry. <i>Journal of Liver Cancer</i> , 2020, 20, 135-147.	1.1	15
206	Chemotherapy for advanced hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, 682-684.	2.8	14
207	Normal enhanced liver fibrosis (<sc>ELF</sc>) values in apparently healthy subjects undergoing a health check-up and in living liver donors in South Korea. <i>Liver International</i> , 2013, 33, 706-713.	3.9	14
208	Normal Controlled Attenuation Parameter Values: A Prospective Study of Healthy Subjects Undergoing Health Checkups and Liver Donors in Korea. <i>Digestive Diseases and Sciences</i> , 2015, 60, 234-242.	2.3	14
209	Transient Elastography is Superior to FIB-4 in Assessing the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B. <i>Medicine (United States)</i> , 2016, 95, e3434.	1.0	14
210	Incidence and risk factors of delayed postpolypectomy bleeding in patients with chronic liver disease. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 618-624.	1.5	14
211	Paper Alert. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 1295-1298.	1.6	14
212	Fibrotic Burden Determines Cardiovascular Risk among Subjects with Metabolic Dysfunction-Associated Fatty Liver Disease. <i>Gut and Liver</i> , 2022, 16, 786-797.	2.9	14
213	Antiviral efficacy of lamivudine versus entecavir in patients with hepatitis B virus-related advanced hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 1528-1534.	2.8	13
214	Longitudinal assessment of alpha-fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 1283-1290.	1.5	13
215	Fibrosis-4 index at diagnosis is associated with all-cause mortality in patients with microscopic polyangiitis and granulomatosis with polyangiitis. <i>BMC Gastroenterology</i> , 2019, 19, 90.	2.0	13
216	An observational study on long-term renal outcome in patients with chronic hepatitis B treated with tenofovir disoproxil fumarate. <i>Journal of Viral Hepatitis</i> , 2020, 27, 316-322.	2.0	13

#	ARTICLE	IF	CITATIONS
217	Effects of transarterial chemoembolization on regulatory T cell and its subpopulations in patients with hepatocellular carcinoma. <i>Hepatology International</i> , 2020, 14, 249-258.	4.2	13
218	Natural History of Untreated HBeAg-Positive Chronic HBV Infection With Persistently Elevated HBV DNA but Normal Alanine Aminotransferase. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00140.	2.5	13
219	Empirical Treatment With Carbapenem vs Third-generation Cephalosporin for Treatment of Spontaneous Bacterial Peritonitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 976-986.e5.	4.4	13
220	Antiviral efficacies of currently available rescue therapies for multidrug-resistant chronic hepatitis B. <i>Clinical and Molecular Hepatology</i> , 2013, 19, 29.	8.9	13
221	A 96-Week Randomized Trial of Switching to Entecavir in Chronic Hepatitis B Patients with a Partial Virological Response to Lamivudine. <i>Antiviral Therapy</i> , 2012, 17, 1563-1570.	1.0	12
222	Long-term Efficacy of Tenofovir Disoproxil Fumarate Monotherapy for Multidrug-Resistant Chronic HBV infection. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1348-1355.e2.	4.4	12
223	Predictive Performance of CAGE-B and SAGE-B Models in Asian Treatment-Naive Patients Who Started Entecavir for Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e794-e807.	4.4	12
224	Association between the severity of liver fibrosis and cardiovascular outcomes in patients with type 2 diabetes. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 1703-1713.	2.8	12
225	Effects of the knockdown of hypoxia inducible factor-1 α expression by adenovirus-mediated shRNA on angiogenesis and tumor growth in hepatocellular carcinoma cell lines. <i>The Korean Journal of Hepatology</i> , 2010, 16, 280.	1.5	12
226	Spontaneous rupture of hepatic metastasis from a thymoma: A case report. <i>World Journal of Gastroenterology</i> , 2016, 22, 9860.	3.3	12
227	Quasispecies and Pre-Existing Drug-Resistant Mutations of Hepatitis B Virus in Patients with Chronic Hepatitis B. <i>Gut and Liver</i> , 2013, 7, 329-334.	2.9	12
228	Liver Cirrhosis, Not Antiviral Therapy, Predicts Clinical Outcome in Cohorts with Heterogeneous Hepatitis B Viral Status. <i>Gut and Liver</i> , 2019, 13, 197-205.	2.9	12
229	What is the role of diagnostic laparoscopy in a gastroenterology unit?. <i>Journal of Gastroenterology</i> , 2007, 42, 881-886.	5.1	11
230	Combination of preS Deletions and A1762T/G1764A Mutations in HBV Subgenotype C2 Increases the Risk of Developing HCC. <i>Intervirology</i> , 2012, 55, 112-118.	2.8	11
231	Serum cytokine levels in chronic hepatitis B patients receiving peginterferon alpha-2a therapy. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2012, 11, 499-506.	1.3	11
232	Acute Variceal Hemorrhage in Patients with Liver Cirrhosis: Weekend versus Weekday Admissions. <i>Yonsei Medical Journal</i> , 2012, 53, 318.	2.2	11
233	Spontaneous Bacterial Peritonitis in Patients with Hepatitis B Virus-Related Liver Cirrhosis: Community-Acquired versus Nosocomial. <i>Yonsei Medical Journal</i> , 2012, 53, 328.	2.2	11
234	Prevention and Management of Variceal Hemorrhage. <i>International Journal of Hepatology</i> , 2013, 2013, 1-6.	1.1	11

#	ARTICLE	IF	CITATIONS
235	Orthotopic liver transplantation after the combined use of locoregional therapy and sorafenib for advanced hepatocellular carcinoma. <i>OncoTargets and Therapy</i> , 2013, 6, 755.	2.0	11
236	Sarcopenia assessed using bioimpedance analysis is associated independently with significant liver fibrosis in patients with chronic liver diseases. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 58-65.	1.6	11
237	Change in the Recurrence Pattern and Predictors over Time after Complete Cure of Hepatocellular Carcinoma. <i>Gut and Liver</i> , 2021, 15, 420-429.	2.9	11
238	Discordance between Liver Biopsy and FibroTest in Assessing Liver Fibrosis in Chronic Hepatitis B. <i>PLoS ONE</i> , 2013, 8, e55759.	2.5	11
239	Silencing of Hypoxia-Inducible Factor-1 β Induces Anti-Tumor Effects in Hepatoma Cell Lines under Tumor Hypoxia. <i>PLoS ONE</i> , 2014, 9, e103304.	2.5	11
240	A Case of Embryonal Sarcoma of the Liver Mimicking a Hydatid Cyst in an Adult. <i>Gut and Liver</i> , 2010, 4, 245-249.	2.9	11
241	Synchronous development of intrahepatic cholangiocarcinoma and hepatocellular carcinoma in different sites of the liver with chronic B-viral hepatitis: two case reports. <i>BMC Research Notes</i> , 2013, 6, 520.	1.4	10
242	Maintaining remission in lamivudine-resistant patients with a virological response to adefovir after lamivudine after stopping lamivudine therapy. <i>Liver International</i> , 2014, 34, 1543-1549.	3.9	10
243	Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide-naïve chronic hepatitis B patients in Korea: data from the clinical practice setting in a single-center cohort. <i>Clinical and Molecular Hepatology</i> , 2014, 20, 261.	8.9	10
244	Efficacy of switching from adefovir to tenofovir in chronic hepatitis B patients who exhibit suboptimal responses to adefovir-based combination rescue therapy due to resistance to nucleoside analogues (SATIS study). <i>Clinical and Molecular Hepatology</i> , 2016, 22, 443-449.	8.9	10
245	Regression of liver fibrosis and hepatocellular carcinoma development after HCV eradication with oral antiviral agents. <i>Scientific Reports</i> , 2022, 12, 193.	3.3	10
246	Clinical Features of Re-Emerging Hepatitis A: An Analysis of Patients Hospitalized during an Urban Epidemic in Korea. <i>Yonsei Medical Journal</i> , 2011, 52, 686.	2.2	9
247	Long-term Outcomes of Antiviral Therapy in Patients With Advanced Chronic HBV Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2811-2813.e1.	4.4	9
248	Predictors of Discordance in the Assessment of Skeletal Muscle Mass between Computed Tomography and Bioimpedance Analysis. <i>Journal of Clinical Medicine</i> , 2019, 8, 322.	2.4	9
249	Hepatocellular Carcinoma Risk According to Regimens for Eradication of Hepatitis C Virus; Interferon or Direct Acting Antivirals. <i>Cancers</i> , 2020, 12, 3414.	3.7	9
250	Evolution of liver fibrosis and steatosis markers in patients with type 2 diabetes after metformin treatment for 2 years. <i>Journal of Diabetes and Its Complications</i> , 2021, 35, 107747.	2.3	9
251	Risk and Risk Score Performance of Hepatocellular Carcinoma Development in Patients With Hepatitis B Surface Antigen Seroclearance. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00290.	2.5	9
252	Spontaneous HBsAg loss in Korean patients: relevance of viral genotypes, S gene mutations, and covalently closed circular DNA copy numbers. <i>Clinical and Molecular Hepatology</i> , 2014, 20, 251.	8.9	9

#	ARTICLE	IF	CITATIONS
253	Comparison of the Effects of Telbivudine and Entecavir Treatment on Estimated Glomerular Filtration Rate in Patients with Chronic Hepatitis B. Gut and Liver, 2015, 9, 776.	2.9	9
254	Clinical Course of Virologic Breakthrough after Emergence of YMDD Mutations in HBeAg-Positive Chronic Hepatitis B. Intervirology, 2008, 51, 293-298.	2.8	8
255	Clinical features and prognosis of hepatocellular carcinoma with respect to preâ€S deletion and basal core promoter mutations of hepatitis B virus Genotype C2. Journal of Medical Virology, 2011, 83, 2088-2095.	5.0	8
256	Lamivudine plus adefovir vs. entecavir in <scp>HB</scp>eAgâ€positive hepatitis B with sequential treatment failure of lamivudine and adefovir. Liver International, 2012, 32, 1179-1185.	3.9	8
257	A Novel Estimation of the Relative Economic Value in Terms of Different Chronic Hepatitis B Treatment Options. PLoS ONE, 2013, 8, e57900.	2.5	8
258	Spontaneous Neoplastic Remission of Hepatocellular Carcinoma. Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The, 2015, 65, 312.	0.4	8
259	Prediction of virologic response to tenofovir monoâ€rescue therapy for multidrug resistant chronic hepatitis B. Journal of Medical Virology, 2016, 88, 1027-1034.	5.0	8
260	An Observational, Multicenter, Cohort Study Evaluating the Antiviral Efficacy and Safety in Korean Patients With Chronic Hepatitis B Receiving Pegylated Interferon-alpha 2a (Pegasys). Medicine (United Tj ETQq0 010rgBT /Overlock 10	0.1	8
261	Prognostic factors of sorafenib therapy in hepatocellular carcinoma patients with failure of transarterial chemoembolization. Hepatology International, 2017, 11, 292-299.	4.2	8
262	Transarterial Chemoembolization in Treatment-NaÃve and Recurrent Hepatocellular Carcinoma: A Propensity-Matched Outcome Analysis. Digestive Diseases and Sciences, 2019, 64, 3660-3668.	2.3	8
263	Feasibility of dynamic risk assessment for patients with repeated trans-arterial chemoembolization for hepatocellular carcinoma. BMC Cancer, 2019, 19, 363.	2.6	8
264	Validation of risk prediction scores for hepatocellular carcinoma in patients with chronic hepatitis B treated with entecavir or tenofovir. Journal of Viral Hepatitis, 2021, 28, 95-104.	2.0	8
265	No influence of hepatic steatosis on the 3â€year outcomes of patients with quiescent chronic hepatitis B. Journal of Viral Hepatitis, 2021, 28, 1545-1553.	2.0	8
266	Liver Stiffness-Based Risk Prediction Model for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease. Cancers, 2021, 13, 4567.	3.7	8
267	Episodic Detectable Viremia Does Not Affect Prognosis in Untreated Compensated Cirrhosis With Serum Hepatitis B Virus DNA <2,000 IU/mL. American Journal of Gastroenterology, 2022, 117, 288-294.	0.4	8
268	A case of isolated metastatic hepatocellular carcinoma arising from the pelvic bone. The Korean Journal of Hepatology, 2012, 18, 89.	1.5	8
269	Conditional Survival Estimates Improve Over Time for Patients with Hepatocellular Carcinoma: An Analysis for Nationwide Korea Cancer Registry Database. Cancer Research and Treatment, 2019, 51, 1347-1356.	3.0	8
270	Combination of Transient Elastography and an Enhanced Liver Fibrosis Test to Assess the Degree of Liver Fibrosis in Patients with Chronic Hepatitis B. Gut and Liver, 2018, 12, 190-200.	2.9	8

#	ARTICLE	IF	CITATIONS
271	Daclatasvir Plus Asunaprevir for the Treatment of Patients with Hepatitis C Virus Genotype 1b Infection: Real-World Efficacy, Changes in Liver Stiffness and Fibrosis Markers, and Safety. <i>Gut and Liver</i> , 2018, 12, 324-330.	2.9	8
272	Comparison of FibroScan-Aspartate Aminotransferase (FAST) Score and Other Non-invasive Surrogates in Predicting High-Risk Non-alcoholic Steatohepatitis Criteria. <i>Frontiers in Medicine</i> , 2022, 9, 869190.	2.6	8
273	Liver-Directed Concurrent Chemoradiotherapy versus Sorafenib in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis. <i>Cancers</i> , 2022, 14, 2396.	3.7	8
274	Association Between Polymorphism of Tumor Necrosis Factor- β Promoter and Response to Lamivudine Treatment in Patients with Chronic Hepatitis B. <i>Digestive Diseases and Sciences</i> , 2010, 55, 2043-2048.	2.3	7
275	External Validation of P2/MS and Comparison with Other Simple Non-invasive Indices for Predicting Liver Fibrosis in HBV-Infected Patients. <i>Digestive Diseases and Sciences</i> , 2010, 55, 2636-2643.	2.3	7
276	Analysis of miRNA expression patterns in human and mouse hepatocellular carcinoma cells. <i>Hepatology Research</i> , 2015, 45, 1331-1340.	3.4	7
277	Clinical Utility of a New Automated Hepatitis C Virus Core Antigen Assay for Prediction of Treatment Response in Patients with Chronic Hepatitis C. <i>Journal of Korean Medical Science</i> , 2016, 31, 1431.	2.5	7
278	Outcome of adefovir add-on lamivudine rescue therapy of up to 5 years in patients with lamivudine-resistant chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 241-247.	2.8	7
279	An evaluation of entecavir for the treatment of chronic hepatitis B infection in adults. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 177-186.	3.0	7
280	Switching from tenofovir and nucleoside analogue therapy to tenofovir monotherapy in virologically suppressed chronic hepatitis B patients with antiviral resistance. <i>Journal of Medical Virology</i> , 2018, 90, 497-502.	5.0	7
281	Refractoriness to transarterial chemoembolization in patients with recurrent hepatocellular carcinoma after curative resection. <i>PLoS ONE</i> , 2019, 14, e0214613.	2.5	7
282	A multicentre study of trends in hepatitis B virus-related hepatocellular carcinoma risk over time during long-term entecavir therapy. <i>Journal of Viral Hepatitis</i> , 2020, 27, 1352-1358.	2.0	7
283	Increased prevalence rate of metabolic syndrome is an independent predictor of cardiovascular disease in patients with antineutrophil cytoplasmic antibody-associated vasculitis. <i>Rheumatology International</i> , 2022, 42, 291-302.	3.0	7
284	Conditional survival estimate in patients with Barcelona Clinic Liver Cancer stage B/C hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy with/without concurrent radiotherapy. <i>Oncotarget</i> , 2017, 8, 79914-79926.	1.8	7
285	When to stop nucleos(t)ide analogues treatment for chronic hepatitis B? Durability of antiviral response. <i>World Journal of Gastroenterology</i> , 2014, 20, 7207.	3.3	7
286	Long-term renal safety between patients with chronic hepatitis B receiving tenofovir vs. entecavir therapy: A multicenter study. <i>Journal of Viral Hepatitis</i> , 2022, 29, 289-296.	2.0	7
287	Anti-Cancer Effects of YAP Inhibitor (CA3) in Combination with Sorafenib against Hepatocellular Carcinoma (HCC) in Patient-Derived Multicellular Tumor Spheroid Models (MCTS). <i>Cancers</i> , 2022, 14, 2733.	3.7	7
288	Clinical Factors Associated with Hepatitis A Virus Seropositivity in HIV-Infected Adults Living in a Country with an Epidemiologic Shift for Hepatitis A Virus Infection. <i>Journal of Korean Medical Science</i> , 2012, 27, 969.	2.5	6

#	ARTICLE	IF	CITATIONS
289	Efficacy of switching to telbivudine plus adefovir in suboptimal responders to lamivudine plus adefovir. <i>World Journal of Gastroenterology</i> , 2013, 19, 7671.	3.3	6
290	Prognostic Indicators for Acute Liver Failure Development and Mortality in Patients with Hepatitis A: Consecutive Case Analysis. <i>Yonsei Medical Journal</i> , 2014, 55, 953.	2.2	6
291	Clinical predictors of silent but substantial liver fibrosis in primary Sjogren's syndrome. <i>Modern Rheumatology</i> , 2016, 26, 576-582.	1.8	6
292	Association between liver fibrosis and appendicular skeletal muscle mass during antiviral therapy in chronic hepatitis B. <i>Digestive and Liver Disease</i> , 2020, 52, 1338-1345.	0.9	6
293	Entecavir and tenofovir on renal function in patients with hepatitis B virus-related hepatocellular carcinoma. <i>Journal of Viral Hepatitis</i> , 2020, 27, 932-940.	2.0	6
294	High body mass index hinders fibrosis improvement in patients receiving long-term tenofovir therapy in hepatitis B virus-related cirrhosis. <i>Journal of Viral Hepatitis</i> , 2020, 27, 1119-1126.	2.0	6
295	Prognostic Value of Alpha-Fetoprotein in Patients Who Achieve a Complete Response to Transarterial Chemoembolization for Hepatocellular Carcinoma. <i>Yonsei Medical Journal</i> , 2021, 62, 12.	2.2	6
296	External validation of CAGE and SAGE scores for Asian chronic hepatitis B patients with well-controlled viremia by antivirals. <i>Journal of Viral Hepatitis</i> , 2021, 28, 951-958.	2.0	6
297	Appraisal of Long-Term Outcomes of Liver-Directed Concurrent Chemoradiotherapy for Hepatocellular Carcinoma with Major Portal Vein Invasion. <i>Journal of Hepatocellular Carcinoma</i> , 2020, Volume 7, 403-412.	3.7	6
298	Influence of Besifovir Dipivoxil Maleate Combined with L-Carnitine on Hepatic Steatosis in Patients with Chronic Hepatitis B. <i>Journal of Korean Medical Science</i> , 2020, 35, e104.	2.5	6
299	Novel Liver Stiffness-Based Nomogram for Predicting Hepatocellular Carcinoma Risk in Patients with Chronic Hepatitis B Virus Infection Initiating Antiviral Therapy. <i>Cancers</i> , 2021, 13, 5892.	3.7	6
300	Transarterial Radioembolization for Unresectable Hepatocellular Carcinoma: Real-Life Efficacy and Safety Analysis of Korean Patients. <i>Cancers</i> , 2022, 14, 385.	3.7	6
301	Systemic treatment in advanced/metastatic hepatocellular carcinoma in the era of targeted therapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 1023-1025.	2.8	5
302	The Use of Health Functional Foods in Gastrointestinal Cancer Patients. <i>Clinical Nutrition Research</i> , 2013, 2, 19.	1.2	5
303	Non-O1, Non-O139 <i>Vibrio cholerae</i> Septicemia after Acupuncture. <i>The Ewha Medical Journal</i> , 2013, 36, S22.	0.2	5
304	Inter-observer variability of response evaluation criteria for hepatocellular carcinoma treated with chemoembolization. <i>Digestive and Liver Disease</i> , 2015, 47, 682-688.	0.9	5
305	Durability of the virological response after lamivudine discontinuation in lamivudine-resistant patients with a complete virological response after lamivudine and adefovir combination therapy. <i>Journal of Medical Virology</i> , 2017, 89, 85-90.	5.0	5
306	HBsAg-negative and anti-HBc-positive in eosinophilic granulomatosis with polyangiitis: a retrospective pilot study. <i>Rheumatology International</i> , 2018, 38, 1531-1538.	3.0	5

#	ARTICLE	IF	CITATIONS
307	Impact of antiviral therapy on risk prediction model for hepatocellular carcinoma development in patients with chronic hepatitis B. <i>Hepatology Research</i> , 2021, 51, 406-416.	3.4	5
308	Screening, confirmation, and treatment rates of hepatitis C virus infection in a tertiary academic medical center in South Korea. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2479-2485.	2.8	5
309	Besifovir dipivoxil maleate: a novel antiviral agent with low toxicity and high genetic barriers for chronic hepatitis B. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 2427-2433.	1.8	5
310	Long-term effects of entecavir and tenofovir treatment on the fibrotic burden in patients with chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 200-207.	2.8	5
311	Serum PD-1 Levels Change with Immunotherapy Response but Do Not Predict Prognosis in Patients with Hepatocellular Carcinoma. <i>Journal of Liver Cancer</i> , 2019, 19, 108-116.	1.1	5
312	Genetic risk factors associated with NAFLD. <i>Hepatoma Research</i> , 0, 2020, .	1.5	5
313	Survival Estimates after Stopping Sorafenib in Patients with Hepatocellular Carcinoma: NEXT Score Development and Validation. <i>Gut and Liver</i> , 2017, 11, 693-701.	2.9	5
314	Multicenter Retrospective Risk Assessment of Esophageal Variceal Bleeding in Patients with Cirrhosis: An Acoustic Radiation Force Impulse Elastography-Based Prediction Model. <i>Gut and Liver</i> , 2019, 13, 206-214.	2.9	5
315	Disease duration and Medsger's severity score are associated with significant liver fibrosis in patients with systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S68-74.	0.8	5
316	Clinical characteristics of acute hepatitis A complicated by acute kidney injury. <i>Scandinavian Journal of Infectious Diseases</i> , 2012, 44, 144-148.	1.5	4
317	Predictors of Refractory Ascites Development in Patients with Hepatitis B Virus-Related Cirrhosis Hospitalized to Control Ascitic Decompensation. <i>Yonsei Medical Journal</i> , 2013, 54, 145.	2.2	4
318	Predictive validation of qualitative fibrosis staging in patients with chronic hepatitis B on antiviral therapy. <i>Scientific Reports</i> , 2019, 9, 15628.	3.3	4
319	Fibrosis-matched outcomes between chronic hepatitis B patients with drug-induced virological response and inactive carriers. <i>Liver International</i> , 2019, 39, 81-89.	3.9	4
320	HKR3 regulates cell cycle through the inhibition of hTERT in hepatocellular carcinoma cell lines. <i>Journal of Cancer</i> , 2020, 11, 2442-2452.	2.5	4
321	Renal safety of tenofovir disoproxil fumarate and entecavir with hepatitis B immunoglobulin in liver transplant patients. <i>Journal of Viral Hepatitis</i> , 2020, 27, 818-825.	2.0	4
322	Risk assessment of hepatocellular carcinoma and liver-related events using ultrasonography and transient elastography in patients with chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1362-1372.	2.0	4
323	Prevalence and Risk Factors of Cardiovascular Disease in Patients with Chronic Hepatitis B. <i>Digestive Diseases and Sciences</i> , 2021, , 1.	2.3	4
324	Dynamics of liver stiffness-based risk prediction model during antiviral therapy in patients with chronic hepatitis B. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, 885-893.	1.6	4

#	ARTICLE	IF	CITATIONS
325	Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response. <i>Clinical and Molecular Hepatology</i> , 2020, 26, 352-363.	8.9	4
326	Validation of Pre-/Post-TACE-Predict Models among Patients with Hepatocellular Carcinoma Receiving Transarterial Chemoembolization. <i>Cancers</i> , 2022, 14, 67.	3.7	4
327	Overview of emerging treatment of non-alcoholic fatty liver disease: more than one drug needed?. <i>Hepatobiliary Surgery and Nutrition</i> , 2019, 8, 522-524.	1.5	3
328	Direct-Acting Antivirals Improve Treatment Outcomes in Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma Treated with Transarterial Chemoembolization: A Nationwide, Multi-center, Retrospective Cohort Study. <i>Digestive Diseases and Sciences</i> , 2020, 66, 2427-2438.	2.3	3
329	Impaired antibacterial response of liver sinusoidal $\text{V}\alpha^3\gamma + \text{V}\alpha^2 + \text{T}$ cells in patients with chronic liver disease. <i>Gut</i> , 2021, , gutjnl-2020-322182.	12.1	3
330	Treatment efficacy by hepatic arterial infusion chemotherapy vs. sorafenib after liver-directed concurrent chemoradiotherapy for advanced hepatocellular carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 3123-3133.	2.5	3
331	Revised Korean Antiviral Guideline Reduces the Hepatitis B-related Hepatocellular Carcinoma Risk in Cirrhotic Patients. <i>Journal of Korean Medical Science</i> , 2021, 36, e105.	2.5	3
332	Correlation of the grade of hepatic steatosis between controlled attenuation parameter and ultrasound in patients with fatty liver: a multi-center retrospective cohort study. <i>Korean Journal of Internal Medicine</i> , 2020, 35, 1346-1353.	1.7	3
333	Prediction of Esophageal Variceal Bleeding in B-Viral Liver Cirrhosis Using the P2/MS Noninvasive Index Based on Complete Blood Counts. <i>Digestion</i> , 2012, 86, 264-272.	2.3	2
334	Partial Virological Response to Adefovir Add-On Lamivudine Rescue Therapy in Patients with Lamivudine-Resistant Chronic Hepatitis B. <i>Digestion</i> , 2013, 87, 196-203.	2.3	2
335	Clonal evolution of multidrug resistant hepatitis B virus during entecavir rescue therapy. <i>Liver International</i> , 2015, 35, 2370-2383.	3.9	2
336	Factors that affect visibility during endoscopic hemostasis for upper GI bleeding: a prospective study. <i>Gastrointestinal Endoscopy</i> , 2015, 81, 1392-1400.	1.0	2
337	A 96-week randomized trial of switching to entecavir in patients who achieved virological suppression on lamivudine therapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 865-871.	2.8	2
338	New Concept of Hepatocellular Carcinoma Treatment with the Tumor Suppressor WDR76 through RAS Degradation. <i>Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The</i> , 2019, 73, 190.	0.4	2
339	Combined use of rosuvastatin and ezetimibe improves hepatic steatosis in patients with dyslipidemia. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 1538-1544.	1.6	2
340	Establishment and validation of a risk prediction model in patients with hepatocellular carcinoma treated with transarterial radioembolization. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 739-747.	1.6	2
341	Pharmacokinetics and safety of evogliptin in hepatically impaired patients. <i>British Journal of Clinical Pharmacology</i> , 2020, 87, 2757-2766.	2.4	2
342	Predictors of Complete Response in Patients with Hepatocellular Carcinoma Treated with Trans-Arterial Radioembolization. <i>Current Oncology</i> , 2021, 28, 965-977.	2.2	2

#	ARTICLE	IF	CITATIONS
343	A Case of Lymphocyte-Rich Hepatocellular Carcinoma in a Patient Who Was Treated for Colon Cancer. <i>Journal of Liver Cancer</i> , 2021, 21, 69-75.	1.1	2
344	The Prognostic Role of On-Treatment Liver Stiffness for Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 467-476.	3.7	2
345	Autoimmune Hepatic Failure Following Acute Hepatitis A is Accompanied by Inflammatory Conversion of Regulatory T Cells. <i>Yonsei Medical Journal</i> , 2020, 61, 100.	2.2	2
346	Performance evaluation of the HepB Typer-Entecavir kit for detection of entecavir resistance mutations in chronic hepatitis B. <i>Clinical and Molecular Hepatology</i> , 2013, 19, 399.	8.9	2
347	Noninvasive Biomarker for Predicting Treatment Response to Concurrent Chemoradiotherapy in Patients with Hepatocellular Carcinoma. <i>Investigative Magnetic Resonance Imaging</i> , 2019, 23, 351.	0.4	2
348	Applications of molecular barcode sequencing for the detection of low-frequency variants in circulating tumour DNA from hepatocellular carcinoma. <i>Liver International</i> , 2022, 42, 2317-2326.	3.9	2
349	Hepatic Angiomyolipoma Mimicking Primary Hepatocellular Carcinoma. <i>Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The</i> , 2016, 68, 284.	0.4	1
350	Histologic Risk Factor for Mortality and Development of Severe Liver Disease in Biopsy-proven Non-alcoholic Fatty Liver Disease. <i>Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The</i> , 2018, 71, 58.	0.4	1
351	Tenofovir-based combination therapy or monotherapy for multidrug-resistant chronic hepatitis B: Long-term data from a multicenter cohort study. <i>Journal of Viral Hepatitis</i> , 2020, 27, 1306-1318.	2.0	1
352	Association Between Curative Treatment after Transarterial Radioembolization and Better Survival Outcomes in Patients with Hepatocellular Carcinoma. <i>Cancer Investigation</i> , 2021, 39, 274-283.	1.3	1
353	Predictors of Sarcopenia in an Obese Asian Population. <i>Nutrition and Cancer</i> , 2022, 74, 505-514.	2.0	1
354	Proposal of a New Risk Score for Patients Treated with Transarterial Chemoembolization due to Recurrent Hepatocellular Carcinoma after Curative Resection: A Multicenter Study. <i>Gut and Liver</i> , 2020, 14, 477-485.	2.9	1
355	Nivolumab for Advanced Hepatocellular Carcinoma with Multiple Lung Metastases after Sorafenib Failure. <i>Journal of Liver Cancer</i> , 2020, 20, 72-77.	1.1	1
356	External Validation of the FSAC Model Using On-Therapy Changes in Noninvasive Fibrosis Markers in Patients with Chronic Hepatitis B: A Multicenter Study. <i>Cancers</i> , 2022, 14, 711.	3.7	1
357	Validation of PH and Varices Risk Scores for Prediction of High-Risk Esophageal Varix and Bleeding in Patients with B-Viral Cirrhosis. <i>Diagnostics</i> , 2022, 12, 441.	2.6	1
358	Subclinical but significant liver fibrosis in patients with ANCA-associated vasculitis. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 117, 26-31.	0.8	1
359	Strategy for Hepatitis C Treatment in Liver Transplant Settings. <i>The Journal of the Korean Society for Transplantation</i> , 2016, 30, 149.	0.2	0
360	Reply to Huang et al.. <i>American Journal of Gastroenterology</i> , 2017, 112, 1478-1479.	0.4	0

#	ARTICLE	IF	CITATIONS
361	IDDF2018-ABS-0028â€...Risk assessment in patients treated with tace due to recurred hepatocellular carcinoma after curative resection. , 2018, , .		0
362	IDDF2018-ABS-0027â€...Influence of hepatic steatosis on the treatment outcomes of entecavir and tenofovir in patients with chronic hepatitis B. , 2018, , .		0
363	Malignant Transformation of Inflammatory Hepatocellular Adenoma into Hepatocellular Carcinoma. Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The, 2018, 72, 267.	0.4	0
364	Step-down strategy in antiviral resistant chronic hepatitis B patients who achieved viral suppression with rescue combination therapy. Future Virology, 2018, 13, 711-717.	1.8	0
365	Liver transplantation for acute on chronic liver disease; when and how?. Annals of Hepato-biliary-pancreatic Surgery, 2021, 25, S8-S8.	0.1	0
366	Risk of Hepatocellular Carcinoma in Patients with Non-alcoholic Fatty Liver Disease. Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The, 2021, 78, 69-71.	0.4	0
367	A Delayed Hepatico-colonic Fistula after Radiofrequency Ablation in Hepatocellular Carcinoma. Korean Journal of Medicine, 2014, 86, 722.	0.3	0
368	Multiple Hepatic Angiomyolipoma Detected by Abdominal Ultrasonography. Journal of Clinical Ultrasound, 2018, 3, 20-23.	0.0	0
369	Persistence of Hepatocellular Carcinoma Risk after Hepatitis C Virus Eradication. Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The, 2020, 75, 308-310.	0.4	0
370	Dickkopf-1 promotes angiogenesis by upregulating VEGF receptor 2-mediated mTOR/p70S6K signaling in hepatocellular carcinoma. American Journal of Cancer Research, 2021, 11, 4788-4806.	1.4	0